First island with zero waste
Tilos marks the first island to achieve 100% diversion from landfill with an 87% recycling rate.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2187 entries already.
Entries by Thomas Gabrielczyk
Santhera licences vamorolone rights to Catalyst Pharmaceuticals
Santhera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc.
BioSenic halts ALLOB development
BioSenic SA has suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB.
Neogap fully takes over TCER Oncology shares
Swedish personalised immunotherapy specialist Neogap Therapeutics AB has acquired the remaining shares of its subsidiary, TCER Oncology AB through two new shareholders.
Antibody provides broad protection vs hantaviruses
An international research team headed by Pablo Guardado-Calvo at Institut Pasteur Paris has demonstrated evaluated antibody efficacy against lethal hantaviruses.
New headquarter in Krakow
The new Krakow headquarters of preclinical CRO Selvita have opened.
3P Biopharmaceuticals lands in the United States.
3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological drugs advances its international expansion with the opening of its first commercial office in the United States located in Boston, Massachusetts.
Progress in the fight against AMR
How to stop the silent pandemic AMR was discussed by 500 experts from 13 countries at the 7th AMR Conference in Basel. At that time, in Brussels, there were two proposals on the table on how to compensate novel resistance-breaking antimicrobials, from which one got the green light in the new pharma legislation.
Syncona launches new gene therapy company Beacon Therapeutics
Syncona Ltd had spun-out the ophtalmology specialist Beacon Therapeutics Holdings Ltd with a £96m Series A financing.
Roche to file MAA for eculizumab competitor
Roche AG has announced positive results from the non-blinded Phase III COMMODORE 1 and 2 trials at the EHA Hybrid Congress in Frankfurt, Germany.